新闻中心
Zennova’s China Manufacturing Facility Is Wrapping Up
来源: | 作者:诺峰药业 | 发布时间: 2020-07-06 | 889 次浏览 | 分享到:
China's first full-dose FDA cGMP manufacturing plant is settled in Chengdu, and the first phase of the project is close to complete by the end of year

Despite the Covid-19 pandemic, the cGMP standard drug manufacturing building of Zennova Pharmaceuticals was sealed roof on June 17, 2020.   On July 5, the R&D and Quality Control Complex was fully topped off.  These milestones indicate that the main structure of Zennova Pharmaceutical’s world-class production buildings has been completed.  Then, it enters the next phase, such as installing the systems of fire fighting, water and electricity, and other interior and exterior construction stages, The complete delivery of the construction civil works is just around the corner.




 


Picture 1. Zennov Pharmaceuticals’ Manufacturing Plant:  Full-dosage form cGMP standard Production Building



 

Picture 2. Zennova Pharmaceutical’s R&D Center & Quality Control Complex

Zennova Pharmaceutical's full-dose form manufacturing plant is located in Chengdu Tianfu International Bio-city.  As planed in its phase one construction, a modern preparation center, logistics center and R&D center of total 50,000 square meters will be designed and built following the top international quality standards. In the future, it will pass the US FDA, EU EMA and China GMP certification. One of Zennova Pharmaceutical’s strategic direction relies on its high-quality standard, full-dose complex dosage form production line, integrates the industrial supply chain, and develops CDMO services for global pharmaceutical companies. The service scope includes oral solid dosage, ophthalmic sterile production lines, injectables, oncology drugs and other high-barrier formulations.


It is expected that by the end of 2020, the phase one of Zennova Pharmaceutical manufacturing plant & R&D Center will complete the construction, and gradually  start the installation of the equipment and production lines in 2021.

While developing innovative drugs in-house, Zennova Pharmaceuticals Group has carried out in-depth cooperation with global scientific research institutions and outstanding pharmaceutical companies to develop innovative drugs with high thresholds, high value, and high technical barriers. It is determined to become a world-class innovative leading pharmaceutical company.

 
The innovative LiquiPuls ™ technology owned by Zennova Pharmaceutical is a breakthrough achievement based on the cutting-edge technology that has 20-years painstaking research.  It fills a number of technical gaps in the pharmaceutical industry and perfectly solves specific problems in Ophthalmic drugs. It is the only industry-leading technology recognized by the US FDA to resolve the most challenging problem in detecting emulsion drug release. Based on this technology, Zennova Pharmaceutical has developed two blockbuster dry eye products, and signed a 20-year sales cooperation agreement with the world’s leading ophthalmic drug companies in the United States.


Zennova Pharmaceutical will continue to uphold a global vision and build a first-class international production base. With its high standards of "technology-drive, innovation-oriented, and quality-emphasize" philosophy, we are becoming a respected industry leader!

  











Picture 3,Picture 4.  Zennova Pharmaceutical Group’s State-of-the-art R&D Center